KAUST researchers have developed deepBlastoid, a deep learning tool for evaluating models of human embryo development, called blastoids. deepBlastoid can evaluate images of blastoids at speeds 1000 times faster than expert scientists, processing 273 images per second. Trained on over 2000 microscopic blastoid images, it assesses the impact of chemicals on blastoid development using over 10,000 images. Why it matters: This AI tool accelerates research into early pregnancy, fertility complications, and the impact of chemicals on embryo development, with implications for reproductive technologies.
A retrospective study in Abu Dhabi, UAE, developed a machine learning-based prognostic system to predict the risk of seven complications in COVID-19 patients using data from 3,352 patient encounters. The system, trained on data from the first 24 hours of admission, achieved high accuracy (AUROC > 0.80) in predicting complications like AKI, ARDS, and elevated biomarkers in geographically split test sets. The models primarily used gradient boosting and logistic regression.
KAUST and Saudi healthtech company amplifAI health have signed an MoU to develop a new disease detection system. The system will combine amplifAI's AI technology with KAUST's HyplexTM hyperspectral imaging, initially for diabetic foot complications. Clinical trials are planned, with aims to reduce amputations and save Saudi Arabia over 2 billion Riyals annually. Why it matters: This partnership showcases the potential of combining Saudi AI and advanced imaging technologies to address pressing healthcare challenges in the region, particularly diabetes.